Skip to main content
Emergent BioSolutions Inc. logo

Emergent BioSolutions Inc. — Investor Relations & Filings

Ticker · EBS ISIN · US29089Q1058 LEI · 549300YW6TUOX8BE5103 US Manufacturing
Open in API
Filings indexed 1,264 across all filing types
Latest filing 2017-02-24 Director's Dealing
Country US United States of America
Listing US EBS

About Emergent BioSolutions Inc.

https://emergentbiosolutions.com/

Emergent BioSolutions Inc. is a life sciences company specializing in solutions for public health threats. The company develops, manufactures, and delivers medical countermeasures for national security and public health preparedness, addressing threats such as anthrax, smallpox, botulism, and Ebola. In addition to its biodefense portfolio, Emergent provides commercial products for endemic health crises, notably the opioid epidemic. The company also offers contract development and manufacturing services through strategic partnerships, leveraging its specialized capabilities to support biopharmaceutical innovators, governments, and non-governmental organizations.

Recent filings

Filing Released Lang Actions
FORM 4/A
Director's Dealing
2017-02-24 English
Regulatory Filings 2017
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions "Item 2.02 Results of Operations and Financial Condition" and states that the company announced financial and operating results for the period ended December 31, 2016. However, it also states that the full text of the press release is attached as Exhibit 99, indicating that the actual financial results are in the press release, not in this document itself. The document length is only 2387 characters, which is quite short and consistent with a brief announcement rather than a full earnings release. According to the "Menu vs Meal" rule, since this document is short and refers to an attached press release for the actual results, it should be classified as a Regulatory Filing (RNS) rather than an Earnings Release (ER).
2017-02-23 English
Regulatory Filings 2017
Regulatory Filings
2017-02-22 English
Board/Management Information 2017
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on the approval of compensation for named executive officers, including cash bonuses, base salaries, target bonuses, and equity awards. It details changes in compensation arrangements and stock awards but does not contain financial statements or comprehensive financial performance data. The key section is Item 5.02, which relates to the departure, election, or appointment of directors or officers and their compensatory arrangements. This aligns with announcements about changes in senior management or board-related information. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is sufficient and contains detailed information about management compensation decisions, not a full annual or quarterly report, nor an earnings release or proxy statement. Hence, the classification is MANG with high confidence.
2017-02-21 English
Regulatory Filings 2017
Regulatory Filings
2017-02-14 English
Major Shareholding Notification 2017
Major Shareholding Notification
2017-02-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.